Publication | Closed Access

Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care

Drug InteractionsThrombosisTherapeutic Drug MonitoringApixaban ConcentrationCardiovascular DiseaseAtrial Fibrillation PatientsPharmacologyPharmacotherapyAtrial FibrillationPublic HealthMedicineAnticoagulantCardiologyPharmacokineticsPharmacoepidemiology